MYC and prostate cancer: As early as 1997, Laxmanan’s group verified c-Myc antisense oligonucleotide (c-Myc-ASO) induces cell death in three kinds of human prostate cancer cell lines, LNCaP, PC3, and DU 145, by decreasing DNA synthesis and cell viability.554 AVI BioPharma Inc. developed a novel antisense phosphorodiamidate morpholino oligomer (PMO), AVI-4126 (234), that can inhibit prostate tumor growth and lung metastasis both in vitro and in vivo by targeting and inhibiting c-Myc translation.